X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1517) 1517
Publication (216) 216
Book Chapter (25) 25
Book Review (14) 14
Conference Proceeding (4) 4
Dissertation (2) 2
Magazine Article (2) 2
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
telaprevir (1494) 1494
index medicus (1023) 1023
humans (984) 984
boceprevir (705) 705
hepatitis c (695) 695
ribavirin (652) 652
hepatitis c virus (611) 611
hepatitis c, chronic - drug therapy (594) 594
antiviral agents - therapeutic use (567) 567
gastroenterology & hepatology (528) 528
male (527) 527
female (495) 495
hepacivirus - genetics (483) 483
middle aged (458) 458
drug therapy, combination (413) 413
genotype (408) 408
interferon (373) 373
adult (350) 350
treatment outcome (350) 350
ribavirin - therapeutic use (337) 337
peginterferon (321) 321
hepacivirus - drug effects (305) 305
protease inhibitors (304) 304
virus-infection (293) 293
interferon-alpha - therapeutic use (283) 283
aged (269) 269
hepatitis (263) 263
hepatitis c, chronic - virology (255) 255
pharmacology & pharmacy (251) 251
plus ribavirin (251) 251
infectious diseases (248) 248
therapy (246) 246
oligopeptides - therapeutic use (240) 240
antiviral agents - administration & dosage (239) 239
antiviral agents - adverse effects (238) 238
virology (238) 238
hepatitis c - drug therapy (237) 237
genotype 1 infection (236) 236
antiviral agents (232) 232
polyethylene glycols - therapeutic use (228) 228
pegylated interferon (223) 223
proline - analogs & derivatives (222) 222
biological response modifiers (217) 217
hcv (213) 213
health aspects (209) 209
infection (206) 206
sustained virological response (206) 206
care and treatment (193) 193
proteases (183) 183
drug therapy (178) 178
recombinant proteins - therapeutic use (176) 176
genetic aspects (166) 166
analysis (164) 164
sofosbuvir (163) 163
chronic hepatitis-c (162) 162
gastroenterology and hepatology (158) 158
ribavirin - administration & dosage (156) 156
chronic hepatitis c (153) 153
viral load (151) 151
virus diseases (151) 151
antiviral agents - pharmacology (149) 149
proline - therapeutic use (143) 143
protease inhibitor (132) 132
cirrhosis (131) 131
interferon-alpha - administration & dosage (128) 128
genotype 1 (124) 124
protease inhibitors - therapeutic use (124) 124
rna, viral - blood (124) 124
triple therapy (123) 123
young adult (123) 123
liver cirrhosis (122) 122
oligopeptides - adverse effects (121) 121
simeprevir (120) 120
peginterferon alpha-2a (119) 119
combination (117) 117
liver (117) 117
hepatitis c - virology (115) 115
microbiology (114) 114
polyethylene glycols - administration & dosage (114) 114
hepacivirus - isolation & purification (112) 112
viral nonstructural proteins - antagonists & inhibitors (111) 111
hepatology (109) 109
hiv (109) 109
combination therapy (107) 107
drug resistance, viral (106) 106
treatment-naive patients (105) 105
genotype & phenotype (102) 102
medicine, general & internal (102) 102
oligopeptides - administration & dosage (101) 101
antiviral therapy (97) 97
resistance (97) 97
anemia (96) 96
ribavirin - adverse effects (96) 96
virus (96) 96
infections (94) 94
hepacivirus - classification (93) 93
viral nonstructural proteins - genetics (93) 93
recombinant proteins - administration & dosage (92) 92
abridged index medicus (91) 91
chronic hcv infection (91) 91
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1401) 1401
Spanish (51) 51
Hungarian (20) 20
German (19) 19
French (16) 16
Japanese (16) 16
Russian (7) 7
Czech (5) 5
Turkish (3) 3
Korean (2) 2
Croatian (1) 1
Italian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Materials Science & Engineering C, ISSN 0928-4931, 12/2019, Volume 105, p. 110012
Telaprevir (TVR) is typically a poorly soluble drug with an extremely low bioavailability of 1.7%. Polymorph modifications cannot improve the solubility of TVR... 
Polymer, Solubility | Solid dispersion | Cytotoxicity | Telaprevir | Dissolution
Journal Article
Enfermedades Infecciosas y Microbiologia Clinica, ISSN 0213-005X, 07/2013, Volume 31, pp. 2 - 6
Telaprevir es el primero de una generación de medicamentos basados en ensamblar andamiajes moleculares con enzimas codificadas por el virus de la hepatitis C,... 
Telaprevir metabolism | Inhibición NS3-4A | Telaprevir pharmacokinetics | CYP3A4 inhibition | Inhibición CYP3A4 | NS3-4A inhibition | Metabolismo de telaprevir | Farmacocinética de telaprevir
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 12/2014, Volume 59, Issue 12, pp. 1777 - 1778
Journal Article
Hepatology, ISSN 0270-9139, 06/2013, Volume 57, Issue 6, pp. 2143 - 2154
Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor with pharmacokinetic properties supportive of once‐daily (QD) dosing.... 
NONRESPONSE | TELAPREVIR | THERAPY | HEPATITIS-C VIRUS | PEGINTERFERON ALPHA-2A | BI 201335 | PHARMACOKINETICS | PROTEASE INHIBITOR BI201335 | 1 INFECTION | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2014, Volume 60, Issue 1, pp. 78 - 86
Background & Aims: Protease inhibitors (PI) with peginterferon/ ribavirin have significantly improved SVR rates in HCV G1 patients. Their use to treat HCV... 
Boceprevir | Protease inhibitors | Early virological response | HCV recurrence | Sustained virological response | Telaprevir | Drug-drug interaction | Liver transplantation
Journal Article
Klimik Dergisi, ISSN 1301-143X, 2017, Volume 30, Issue 3, pp. 126 - 130
Objective: We aimed to evaluate results of telaprevir, pegylated interferon and ribavirin treatment of patients with hepatitis C virus (HCV) genotype 1b... 
Gaziantep | Hepacivirus | Telaprevir | Hepatitis | Interferon
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2017, Volume 40, Issue 9, pp. 1525 - 1529
To compare the rate of treatment discontinuation due to adverse events for telaprevir-based triple (T/PR) and pegylated interferon-alfa-2b and ribavirin (PR)... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 20, pp. 1889 - 1898
Journal Article
Journal Article
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2017
In this study, a nationwide database was used to identify the risk factors for treatment discontinuation due to adverse events during telaprevir,... 
regional differences | ribavirin | telaprevir | nationwide database | hepatitis C | interferon
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9956, pp. 1756 - 1765
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2014, Volume 370, Issue 3, pp. 211 - 221
Journal Article